Phase II safety and efficacy study of panitumumab in patients with KRAS exon2 colorectal cancer refractory for cetuximab.

Trial Profile

Phase II safety and efficacy study of panitumumab in patients with KRAS exon2 colorectal cancer refractory for cetuximab.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2016 New trial record
    • 11 Oct 2016 Primary end point (Progression-free survival rate) has not been met.
    • 11 Oct 2016 Results assessing efficacy and safety presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top